Post by Tony Crispino on Dec 20, 2013 22:18:33 GMT -8
Just reporting...
The investigators concluded, “Reporting of adverse events in oncology publications of randomized trials is suboptimal and characterized by substantial selectivity and heterogeneity. The development of oncology-specific standards for adverse event reporting should be established to ensure consistency and provide critical information required for medical decision-making.”
Asco Wire
Key Points:
Studies had a median completeness score of 8, out of 14.
Lack of specified funding source and earlier year of publication were significantly associated with lower completeness scores.
The investigators concluded, “Reporting of adverse events in oncology publications of randomized trials is suboptimal and characterized by substantial selectivity and heterogeneity. The development of oncology-specific standards for adverse event reporting should be established to ensure consistency and provide critical information required for medical decision-making.”
Asco Wire
Key Points:
Studies had a median completeness score of 8, out of 14.
Lack of specified funding source and earlier year of publication were significantly associated with lower completeness scores.
